CRBP
vs
S&P 500
CRBP
S&P 500
Over the past 12 months, CRBP has outperformed S&P 500, delivering a return of +24% compared to the S&P 500's +18% growth.
Stocks Performance
CRBP vs S&P 500
Performance Gap
CRBP vs S&P 500
Performance By Year
CRBP vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Corbus Pharmaceuticals Holdings Inc
Glance View
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company is headquartered in Norwood, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2014-10-24. The Company’s pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. The firm pipeline includes Anti-integrin monoclonal antibodies (mAbs), Cannabinoid receptor type 1 (CB1) and Lenabasum. The mAbs is for the treatment of cancer and fibrosis that inhibit the activation of Transforming growth factor β (TGFβ). Its CRB-601 is an anti-αvβ8 mAb being developed as a potential treatment for solid tumors in combination with existing therapies, including checkpoint inhibitors. Cannabinoid receptor type 1 (CB1) is an inverse agonist designed to treat obesity and related metabolic diseases. Lenabasum is a novel, synthetic, oral molecule that selectively activates cannabinoid receptor type 2 (CB2).
